Krystal Biotech Inc (KRYS)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.12 | 1.11 | 1.09 | 1.07 | 1.05 | 1.05 | 1.05 | 1.09 | 1.07 | 1.07 | 1.08 | 1.12 | 1.06 | 1.10 | 1.06 | 1.03 | 1.06 | 1.03 | 1.03 | 1.03 |
Krystal Biotech Inc's solvency ratios indicate strong financial health, with consistently low levels of debt relative to assets, capital, and equity. The Debt-to-assets ratio, Debt-to-capital ratio, and Debt-to-equity ratio have all remained at 0.00 since March 2020, demonstrating that the company is not relying heavily on debt to finance its operations.
Furthermore, the Financial leverage ratio has been relatively stable around the range of 1.03 to 1.12 from March 2020 to December 2024. This suggests that the company is maintaining a healthy balance between debt and equity in its capital structure.
Overall, these solvency ratios suggest that Krystal Biotech Inc has a strong ability to meet its financial obligations and is not at risk of financial distress due to high levels of debt.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | 1.10 | -0.84 | -2.70 | -2.19 | -5.91 | -6.12 | -5.75 | — | — | — | — | -45.76 | -38.08 | -34.08 | -27.75 | — | — | — | -43.05 |
Interest coverage ratio is a financial metric that indicates a company's ability to meet its interest payments on outstanding debt. It is calculated by dividing earnings before interest and taxes (EBIT) by the company's interest expenses. A higher interest coverage ratio suggests that the company is more capable of servicing its interest obligations.
Analyzing the interest coverage ratio of Krystal Biotech Inc from March 31, 2020, to December 31, 2024, shows a fluctuating trend. The ratio was negative in most quarters, indicating that the company's earnings were insufficient to cover its interest expenses during those periods. This negative trend raises concerns about the company's financial health and its ability to meet its debt obligations.
The interest coverage ratio improved slightly in the later periods, reaching positive territory by September 30, 2024. This improvement suggests that the company's earnings have strengthened, allowing it to cover its interest expenses comfortably. However, the ratio is still relatively low, indicating that Krystal Biotech Inc may still face challenges in meeting its interest payments in the future.
Overall, the analysis of Krystal Biotech Inc's interest coverage ratio highlights the importance of closely monitoring the company's financial performance and debt management strategies to ensure long-term sustainability and stability.